Concert Pharmaceuticals CEO and leadership

Dr. Roger Tung is the scientific founder, President, and CEO of Concert Pharmaceuticals, which he co-founded in 2006. Before Concert, Roger worked in venture-backed start-up and major pharmaceutical companies; including Vertex Pharmaceuticals, as a founding scientist and most recently Vice President of Drug Discovery; Merck; and E.R. Squibb & Sons. At Vertex, he co-invented the marketed HIV protease inhibitors Lexiva® and Agenerase®, and oversaw the discovery of Incivek® and Kalydeco®, approved respectively to treat HCV infection and cystic fibrosis caused by the G551D CFTR mutation. Roger has published widely and been granted 60 U.S. patents. He received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison from Professor Daniel H. Rich. Roger is a scientific advisor to public and private biotech companies and serves on the Board of Visitors of the University of Wisconsin-Madison School of Pharmacy.

Ms. Nancy Stuart has over 20 years of biotechnology and pharmaceutical industry experience and currently serves as Chief Operating Officer of Concert Pharmaceuticals, Inc. Prior to joining Concert in July 2006, she held senior level business and drug development positions at RRD International, Scion Pharmaceuticals, Kinetix/Amgen Inc., Vertex Pharmaceuticals, Inc. and Genzyme Corporation. At Kinetix, Ms. Stuart established the business development strategy that culminated in its $170 million acquisition by Amgen. At Vertex, she served as Vice President of Program Planning and Management and was responsible for Vertex’s strategic partnerships and global drug development programs. In addition, she co-directed the development of Agenerase®, Vertex’s HIV protease inhibitor and initiated the Thyrogen® program for thyroid cancer testing at Genzyme. She has had extensive experience in raising private capital for start up biotechnology companies. Ms. Stuart is a member of the Board of Directors for the YMCA of Greater Boston. She holds a Bachelor of Science from the University of Michigan, and an MBA from the Simmons College Graduate School of Management.

leadership positions in the discovery and development of novel drugs and pharmaceutical products

Specialties: drug development, clinical research and development, pharmacology, regulatory strategy, CNS drug development, pulmonary drug delivery, drug-device combination products,cystic fibrosis

Results-oriented legal and operational executive with 17 years of experience leading corporations through all stages of the corporate lifecycle. Trusted advisor and strategic business partner to boards of directors and executive management. Proven ability to build and manage respected legal, intellectual property and operational teams to effectively service organizational needs.

Dr. Roger Tung is the scientific founder, President, and CEO of Concert Pharmaceuticals, which he co-founded in 2006. Before Concert, Roger worked in venture-backed start-up and major pharmaceutical companies; including Vertex Pharmaceuticals, as a founding scientist and most recently Vice President of Drug Discovery; Merck; and E.R. Squibb & Sons. At Vertex, he co-invented the marketed HIV protease inhibitors Lexiva® and Agenerase®, and oversaw the discovery of Incivek® and Kalydeco®, approved respectively to treat HCV infection and cystic fibrosis caused by the G551D CFTR mutation. Roger has published widely and been granted 60 U.S. patents. He received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison from Professor Daniel H. Rich. Roger is a scientific advisor to public and private biotech companies and serves on the Board of Visitors of the University of Wisconsin-Madison School of Pharmacy.

Dr. Roger Tung is the scientific founder, President, and CEO of Concert Pharmaceuticals, which he co-founded in 2006. Before Concert, Roger worked in venture-backed start-up and major pharmaceutical companies; including Vertex Pharmaceuticals, as a founding scientist and most recently Vice President of Drug Discovery; Merck; and E.R. Squibb & Sons. At Vertex, he co-invented the marketed HIV protease inhibitors Lexiva® and Agenerase®, and oversaw the discovery of Incivek® and Kalydeco®, approved respectively to treat HCV infection and cystic fibrosis caused by the G551D CFTR mutation. Roger has published widely and been granted 60 U.S. patents. He received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison from Professor Daniel H. Rich. Roger is a scientific advisor to public and private biotech companies and serves on the Board of Visitors of the University of Wisconsin-Madison School of Pharmacy.

leadership positions in the discovery and development of novel drugs and pharmaceutical products

Specialties: drug development, clinical research and development, pharmacology, regulatory strategy, CNS drug development, pulmonary drug delivery, drug-device combination products,cystic fibrosis